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ABSTRACT
Background: In the UK, the care of young people with
diabetes has focused predominantly on type 1 diabetes
(T1D). However, young-onset T2D has become
increasingly prevalent. At present, it is unclear which
type of diabetes represents the more adverse
phenotype to develop complications. This study aims
to determine the complication burden and its predictive
factors in young-onset T2D compared with T1D.
Methods: A cross-sectional study using a hospital
diabetes register to identify patients with young-onset
T2D and T1D. Young-onset T2D was defined as age of
diagnosis below 40 years. The T1D cohort with a
similar age of diagnosis was used as a comparator.
Data from the last clinic visit was used for analysis.
Clinical characteristics and diabetes complications were
evaluated at diabetes durations <10, 10–20, and
>20 years. Predictive factors for diabetes complications
(age, sex, glycated hemoglobin, creatinine, diabetes
duration, hypertension, dyslipidemia, and body mass
index >25) were determined by logistic regression
analysis.
Results: Data were collected on 1287 patients, of
which 760 and 527 had T1D and T2D, respectively. In
all diabetes durations, the T2D cohort had an older age
of onset (p<0.0005) with a higher prevalence of
obesity, hypertension, and dyslipidemia (all p<0.0005)
while glycemic control was similar in both groups.
Cardiovascular disease (p<0.005) and neuropathy
(p<0.05) were more prevalent in the young-onset T2D
cohort in all diabetes durations. There was no
difference in retinopathy. Cardiovascular disease was
predominantly due to ischemic heart disease. Stroke
and peripheral vascular disease became significantly
higher in T2D after 20 years duration. After controlling
for traditional risk factors, young-onset T2D was an
independent predictor for cardiovascular disease
(p<0.005) and neuropathy (p<0.05) but not for
retinopathy.
Conclusions: Young-onset T2D is a more aggressive
phenotype than T1D to develop diabetes complications,
particularly for ischemic heart disease and neuropathy.
BACKGROUND
Type 2 diabetes (T2D) in young adults has
become increasingly prevalent. The propor-
tion of newly diagnosed patients with T2D
below the age of 40 years has increased sig-
niﬁcantly from 5.9% to 12.4% between 1991
and 2010 in the UK.1 It heralds a prolonged
lifetime exposure to an adverse diabetic
milieu with complications occurring at an
economically productive young age.
In the UK, the clinical care of young
people with diabetes has focused predomin-
antly on T1D for a variety of reasons. First, it
is the most common form of diabetes in this
age group. Second, T1D is often perceived as
more severe than T2D given its ﬂorid clinical
presentation and the absolute need for life-
saving insulin treatment from diagnosis. This
perception is further strengthened by the
adverse mortality outcome for young people
with T1D.2 Third and most importantly,
intensive intervention has been shown to
improve the complication outcomes in this
young cohort.3
Given the susceptibility of young-onset
T2D for premature complications,4 it will be
clinically pertinent to determine which type
of diabetes is more deleterious when its
onset occurs at a young age. There is evi-
dence to suggest that young-onset T2D has
worse complication and prognostic outcomes
compared with patients with T1D with a
similar age of diagnosis.5–8 At present, it is
unknown whether the ﬁndings from these
studies also apply to a UK population. The
Key messages
▪ Although type 1 diabetes is the most common
form of diabetes diagnosed below age 40, type 2
diabetes has become increasingly prevalent
among the young population in the UK.
▪ It remains unknown whether there is any differ-
ence in the propensity to develop complications
between these two types of young-onset
diabetes.
▪ Young-onset type 2 diabetes represents the
more adverse phenotype with a worse cardiome-
tabolic profile and greater risk to develop micro-
vascular and macrovascular complications than
type 1 diabetes.
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objective of this study is to address this knowledge gap,
which may challenge the current focus in the care of
young people with diabetes.
METHODS
Study population
The study population was identiﬁed from a hospital elec-
tronic diabetes register which recorded clinical details of
patients with T1D and T2D who attended clinics at the
Northern General Hospital and Royal Hallamshire
Hospital in Shefﬁeld, UK. Clinical data were routinely
entered into the database each time the patients were
seen in these clinics. This diabetic population was
referred by general practitioners predominantly to
improve poor diabetes control and for optimization of
risk factor management. Other reasons include those on
hospital follow-up for chronic diabetes-related complica-
tions and newly diagnosed diabetes identiﬁed from hos-
pital admissions.
Definition of study population
Young-onset T2D was deﬁned as age of diagnosis below
40 years as stipulated in the National Institute for Health
and Care Excellence (NICE) guideline.9 Since the
youngest age of diagnosis for T2D was 15 years, the age
of diabetes onset between 15 and 39 years was chosen to
deﬁne this cohort. Patients with T1D with a similar age
of diagnosis were used as a comparator. This is to minim-
ize the bias associated with difference in the age of dia-
betes onset. T2D was deﬁned as those whose diabetes
was controlled by oral hypoglycemic agents without the
need for continuous insulin therapy within the ﬁrst year
of diagnosis and/or with negative autoantibody status
(glutamic acid decarboxylase, islet cell antibody, and
islet-antigen-2). T1D was deﬁned by the absolute
requirement for insulin therapy within 1 year of diagno-
sis and/or with positive autoantibody status. Those with
diabetes etiology due to maturity onset diabetes of the
young, gestational diabetes and secondary diabetes were
excluded.
Data collection
This was a cross-sectional study focused on the hospital dia-
betes population. Data were extracted from the diabetes
register in 2009 as part of the service evaluation exercise.
The most recent data obtained from the last clinic visit
were used for analysis. Patients with incomplete data were
excluded. For each patient, complete data on clinical
characteristics, laboratory tests (glycated hemoglobin
(HbA1c), full lipid proﬁle (total cholesterol, high-density
lipoprotein (HDL), and triglyceride), and kidney func-
tion) and diabetes-related complications pertaining to
microvascular disease (retinopathy and peripheral neur-
opathy) and cardiovascular disease (CVD; ischemic heart
disease, peripheral vascular disease, and stroke) were col-
lected. These medical conditions were entered into the
database using the International Classiﬁcation of Diseases
10 and Read codes. At the time of data extraction, microal-
buminuria was not routinely screened in patients with
T2D; hence, these data were not included in the study ana-
lysis. However, screening for other microvascular complica-
tions (retinopathy and neuropathy) was routinely
performed in all patients. Apart from age of onset, com-
paring the outcomes of T1D and T2D is often confounded
by the differences in disease duration. To minimize this
bias and to assess the impact of diabetes duration, study
subjects were stratiﬁed into three categories of diabetes
duration, namely, <10, 10–20, and >20 years. Clinical
characteristics and the diabetes complication burden were
analyzed in each group.
Retinopathy was detected from digital photography
which was performed as part of the city-wide diabetes eye
screening program. Peripheral neuropathy was detected by
clinical examination (monoﬁlament test, vibration sense),
nerve conduction test, or presence of sensory symptoms.
Ischemic heart disease was deﬁned as myocardial infarction
(STand non-STelevation), stable and unstable angina and/
or coronary intervention. Peripheral vascular disease was
deﬁned as a history of leg amputation for ischemia, periph-
eral revascularization, or ankle-brachial index <0.9. Stroke
was deﬁned as ischemic stroke proven on a CT scan or
history of transient ischemic attack. Hypertension was
deﬁned as blood pressure >140/80 mmHg or >130/
80 mmHg with diabetic complications or on antihyperten-
sive treatment while dyslipidemia was deﬁned as fasting tri-
glyceride >1.7 mmol/L and/or HDL <1.03 mmol/L for
male or <1.29 mmol/L for female or on speciﬁc treatment
for this condition. Overweight and obesity were deﬁned by
body mass index (BMI) greater than 25 kg/m2.
Statistical analysis
All statistical analyses were performed using the
Statistical Package for Social Science V.16.0 for Windows
(SPSS Inc, Chicago, Illinois, USA). Continuous data
were expressed as mean±SD, while categorical data were
expressed as percentage. The normality of continuous
data distribution was assessed with the Kolmogorov-
Smirnov test to determine the appropriate method for
parametric or non-parametric statistical analysis.
Continuous data were analyzed by Student’s t test or the
Mann Whitney U test, while the χ2 test was used to
compare categorical variables between two groups. The
χ2 value for the trend was used to determine the signiﬁ-
cance of trends in frequency across different groups.
Logistic regression analysis was conducted to estimate
the odds of diabetes complications associated with the
type of diabetes (type 2 vs 1), controlled for variables
found to be signiﬁcant in the univariate analysis. The
independent variables used were age, sex, HbA1c, cre-
atinine, diabetes duration, hypertension, dyslipidemia,
and BMI>25 kg/m2. A p value of <0.05 was considered
signiﬁcant.
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RESULTS
Subject characteristics
There were 2681 patients with age of diagnosis below
40 years for both types of diabetes, of which 1394 had
an incomplete data set and were excluded from the ana-
lysis. A total of 1287 patients with a complete data set
were included in this analysis, of which 760 and 527 had
T1D and T2D, respectively. The clinical characteristics of
the study subjects are shown in table 1. Overall, patients
with T1D had a younger age of diabetes onset and
longer disease duration. The mean age of diagnosis was
25.8±6.9 and 32.5±5.9 years (p<0.0005) while diabetes
duration was 20.4±12.9 and 15.0±10.3 years (p<0.0005)
for T1D and T2D, respectively. There was an excess of
males, particularly in the T1D cohort (60.5% vs 50.7%,
p<0.005). Glycemic control was similar but suboptimal
(>7% (53 mmol/mol)) in both groups in all categories
of diabetes duration.
There were some differences in the treatment
between young-onset T1D and T2D. Overall, the use of
antihypertensive and statin medications was signiﬁcantly
higher among the T2D cohort, apart from those with
diabetes duration >20 years, where the statin treatment
was similar (table 1). As expected, the proportion of
patients with T2D on insulin treatment increased with
disease duration with almost all the patients being
insulin-dependent after 20 years duration (<10 vs 10–20
vs >20 years; 44.9% vs 76.8% vs 93.1%, p<0.0005 for
trend).
The importance of obesity in young-onset T2D was
illustrated by the progressive rise in its prevalence with
increasing BMI regardless of diabetes duration, in con-
trast to T1D (p<0.0005 vs T1D for all diabetes durations;
ﬁgure 1).
Cardiovascular risk factors
An adverse cardiovascular risk proﬁle was observed
among the T2D cohort in all categories of diabetes dur-
ation with a higher prevalence of obesity, hypertension,
dyslipidemia, and clustering of cardiovascular risk factors
(obesity, hypertension, dyslipidemia) compared with T1D
(p<0.0005 vs T1D for all risk factors; table 1). To explore
whether these risk factors had a signiﬁcant presence in
the early stages of the diabetes condition, the cardiovas-
cular risk proﬁle was analyzed within 5 years of diagnosis.
Clinical data were available for 81 and 72 patients with
T1D and T2D, respectively. Despite the short diabetes
duration (T1D vs T2D; 2.5±1.2 vs 2.7±1.2 years, p=NS),
the prevalence of obesity (T1D vs T2D; 50.6 vs 91.7%,
p<0.0005), hypertension (T1D vs T2D; 27.2 vs 44.4%,
p=0.029), dyslipidemia (T1D vs T2D; 38.3 vs 76.4%,
p<0.0005), and risk factor clustering (T1D vs T2D; 38.3 vs
80.6%, p<0.0005) were signiﬁcantly greater in T2D.
Among those who were recently diagnosed (diabetes dur-
ation <1 year), the adverse cardiovascular risk proﬁle was
again more prevalent in young-onset T2D (T1D (n=19)
vs T2D (n=14): risk factor clustering; 42.1 vs 85.7%,
p=0.015).
Obesity increased the burden of hypertension and dys-
lipidemia in both types of diabetes (p<0.0005), but to a
greater extent in the T2D cohort (p<0.005 vs T1D for
hypertension and dyslipidemia with BMI>25 kg/m2;
table 2). More patients with T2D had dyslipidemia
regardless of the BMI. In contrast, there was no differ-
ence in the prevalence of hypertension when the BMI
was less than 25 kg/m2.
Diabetes complications
The relationship between diabetes duration and CVD
and microvascular complications is shown in table 3. As
expected, the complication burden increased with
disease duration in both types of diabetes. Within
10 years of diagnosis, CVD and neuropathy were signiﬁ-
cantly higher in the T2D cohort and this trend persisted
for the remainder of diabetes duration. The burden of
CVD was driven predominantly by ischemic heart
disease. In contrast, retinopathy was similar in both
groups across all diabetes durations and this differential
burden in neuropathy and retinopathy complications
occurred despite similar glycemic control. Stroke and
peripheral vascular disease became signiﬁcantly higher
only among the T2D cohort after 20 years duration.
Compared with T1D, the CVD and neuropathic compli-
cations occurred earlier in the diabetic disease process
in T2D. For an equivalent prevalence of CVD complica-
tion (∼14%), the T2D cohort was much younger (T2D
vs T1D; 48.4 vs 57.8 years, p<0.0005) and had shorter
diabetes duration (T2D vs T1D; 14.2 vs 31.4 years,
p<0.0005). For neuropathy (prevalence ∼12–15%), the
T2D cohort had a much shorter diabetes duration (T2D
vs T1D; 5.6 vs 14.2 years, p<0.0005).
Predictors of diabetes complications
The relationship between independent risk factors for
the development of diabetes complications was analyzed
by logistic regression analysis (table 4). Age, diabetes
duration, creatinine, hypertension, dyslipidemia, and
obesity were signiﬁcant predictors for CVD while for
microvascular complications, the signiﬁcant factors were
age, male sex (for neuropathy), diabetes duration, cre-
atinine, HbA1c, hypertension, and obesity. Interestingly,
cardiovascular risk factors (obesity, hypertension, and
dyslipidemia) were more strongly associated with neur-
opathy than retinopathy. After controlling for these vari-
ables, T2D was found to be a signiﬁcant independent
predictor for CVD and neuropathy but not for retinop-
athy. The association was strongest for CVD.
DISCUSSION
The principal concern with diabetes diagnosed at a young
age is the development of complications at an earlier stage
of life. Comparative analysis of complication characteristics
between the increasingly prevalent young-onset T2D and
T1D, the most common form of diabetes in the young, is
clinically relevant. This is the ﬁrst study in the UK to
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Table 1 Clinical characteristics of study subjects
Diabetes duration (years)
0–10 10–20 >20
Type 1 (n=197) Type 2 (n=211) p Value Type 1 (n=190) Type 2 (n=151) p Value Type 1 (n=373) Type 2 (n=165) p Value
Current age (years) 33.9 (7.7) 39.5 (6.3) <0.0005 41.6 (6.9) 48.4 (6.4) <0.0005 57.8 (10.7) 61.4 (8.3) <0.0005
Age of diagnosis (years) 27.5 (7.3) 32.6 (5.5) <0.0005 25.9 (6.5) 32.7 (5.3) <0.0005 24.9 (6.8) 32.3 (6.8) <0.0005
DM duration (years) 5.2 (2.6) 5.6 (2.4) NS 14.4 (2.8) 14.2 (2.9) NS 31.4 (8.4) 27.6 (7.4) <0.0005
Systolic BP (mm Hg) 127.4 (16.9) 133.3 (19.5) 0.001 130.4 (17.1) 138.1 (19.1) <0.0005 138.8 (17.5) 141.2 (20.6) NS
Diastolic BP (mm Hg) 75.0 (12.4) 79.8 (10.8) <0.0005 77.2 (9.8) 76.8 (11.8) NS 73.7 (9.8) 71.3 (8.7) 0.005
BMI (kg/m2) 26.6 (5.0) 34.7 (8.6) <0.0005 27.6 (4.8) 34.9 (7.1) <0.0005 27.6 (4.7) 33.4 (6.9) <0.0005
HbA1c (%)
(mmol/mol)
8.7 (1.9)
72 (21)
8.8 (2.0)
74 (22)
NS 8.9 (1.8)
74 (18)
9.2 (2.0)
77 (21)
NS 8.6 (1.3)
70 (14)
8.9 (1.7)
74 (18)
NS
Creatinine (µmol/L) 77.3 (55.6) 73.0 (20.1) NS 80.6 (26.9) 80.7 (48.7) NS 94.7 (69.1) 103.8 (60.9) NS
Total cholesterol (mmol/L) 4.8 (1.1) 4.7 (1.5) 0.002 4.7 (1.0) 4.4 (1.4) <0.0005 4.4 (0.9) 4.1 (0.9) <0.0005
HDL (mmol/L) 1.7 (0.4) 1.0 (0.3) <0.0005 1.5 (0.5) 1.0 (0.3) <0.0005 1.6 (0.5) 1.2 (0.3) <0.0005
Triglyceride (mmol/L) 1.7 (4.3) 2.8 (3.3) <0.0005 1.3 (0.9) 2.7 (3.4) <0.0005 1.1 (0.9) 2.0 (1.3) <0.0005
BMI>25 kg/m2 (%) 57.4 90.5 <0.0005 70.0 96.0 <0.0005 70.0 90.9 <0.0005
Hypertension (%) 26.9 55.9 <0.0005 43.2 78.1 <0.0005 71.0 87.3 <0.0005
Dyslipidemia (%) 36.5 80.6 <0.0005 31.1 82.1 <0.0005 23.3 71.5 <0.0005
Risk factors >2 (%) 37.6 82.5 <0.0005 46.8 90.7 <0.0005 58.4 92.1 <0.0005
Antihypertensive (%) 10.6 38.3 <0.0005 28.6 67.1 <0.0005 57.7 75.9 <0.0005
Statin (%) 24.5 59.0 <0.0005 48.1 73.5 <0.0005 76.6 73.1 NS
BMI, body mass index; BP, blood pressure; DM, diabetes mellitus; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; NS, not significant.
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speciﬁcally assess the burden of diabetes complications
and its predictive risk factors in these two cohorts. The
atherogenic milieu was present early in the natural history
of young-onset T2D and obesity incurred a greater burden
of cardiovascular risk factors in this cohort. CVD and neur-
opathy were substantially higher in T2D and occurred at
an earlier stage than T1D. Ischemic heart disease
accounted for the majority of CVD. Despite the similar gly-
cemic control and diabetes duration, neuropathic compli-
cation was higher in T2D, in contrast to retinopathy, which
was similar in both types of diabetes. After controlling for
traditional risk factors, young-onset T2D emerged as an
independent predictive factor for CVD and neuropathy,
but not for retinopathy.
Recent population-based studies from Australia,5
Canada,6 the USA,7 and Hong Kong8 analyzed the differ-
ential burden of diabetes-related complications among
young-onset T1D and T2D with the age of diabetes onset
ranging from children to young adults. Constantino et al5
showed that young adults with T2D (age of diagnosis
25.6 years) had a higher CVD (ischemic heart disease
and stroke), albuminuria, and neuropathy with a 2-fold
increase in mortality predominantly from CVD but no
difference in retinopathy. Dart et al6 and Jaiswal et al7
showed that young-onset T2D with age of diagnosis
between 11 and 14 years had higher rates of neuropathy
and albuminuria with no signiﬁcant difference in retin-
opathy.6 In a Chinese population, Luk et al8 showed that
CVD (coronary heart disease and stroke), nephropathy
(albuminuria and end-stage renal disease), neuropathy,
and retinopathy complications were higher in young-
onset T2D (age of diagnosis 33 years). Taken altogether,
these observations demonstrated the consistent pattern
of a higher burden of CVD, neuropathy, and
Figure 1 Distribution of body mass index (BMI) between young-onset type 1 diabetes (T1D) and T2D at different diabetes
durations.
Table 2 The differing impact of increased BMI on cardiovascular risk factors in young-onset type 1and type 2 diabetes
Type 1 diabetes Type 2 diabetes
BMI<25 kg/m2
(n=259)
BMI>25 kg/m2
(n=501) p Value
BMI<25 kg/m2
(n=46)
BMI>25 kg/m2
(n=481) p Value
Hypertension
(%)
36.7 60.9 <0.0005 39.1* 75.3† <0.0005
Dyslipidemia
(%)
19.3 33.5 <0.0005 56.5‡ 80.2§ 0.001
*p=NS versus type 1 diabetes with BMI<25 kg/m2.
†p<0.005 versus type 1 diabetes with BMI>25 kg/m2.
‡p<0.005 versus type 1 diabetes with BMI<25 kg/m2.
§p<0.005 versus type 1 diabetes with BMI>25 kg/m2.
BMI, body mass index; NS, not significant.
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nephropathy in young-onset T2D compared with T1D
with probable equivalence for retinopathy. With the
exception of nephropathy due to lack of albuminuria
data, the ﬁndings from this study are consistent with the
published literature with a similar observation in young
adults with T2D (age of diagnosis 32.5 years) in a UK
population. It appears that young-onset T2D
is universally a more adverse phenotype compared
with T1D.
There is other evidence to support the hypothesis of
young-onset T2D being the less favorable phenotype
prognostically. In a Swedish study of patients with dia-
betes aged 15–34 years compared with the general popu-
lation, the standardized mortality ratio was higher for
T2D than for the T1D cohort (2.9 vs 1.8).10 The prob-
ability for complication-free survival was signiﬁcantly
lower for youths aged up to 18 years with T2D versus
T1D.6 Youths with T2D (mean age 17 years) have been
shown to have increased arterial stiffness11 and a worse
lipid proﬁle12 than patients of similar age with T1D ,
indicating increased risk for premature CVD.
The differential burden of retinopathy and neuropathy
between young-onset T1D and T2D is consistent with
other studies.5 6 This difference is not attributable to gly-
cemia and diabetes duration, given the equipoise in
these variables in both types of diabetes. Since
cardiovascular risk factors (obesity, hypertension, and dys-
lipidemia) were signiﬁcantly higher in T2D and have a
stronger association with neuropathy, these factors may
play an etiological role in this complication. This hypoth-
esis is supported by the ﬁndings from several large
epidemiological studies implicating these cardiometa-
bolic risk factors in the pathogenesis of diabetic neur-
opathy.13–15 This association has also been observed
among young adults with T2D.7 In contrast, glycemia and
disease duration are the main contributors to the evolu-
tion of retinopathy in both types of diabetes with cardio-
metabolic risk factors playing a less signiﬁcant role.
Young adults with T2D have higher cardiovascular
events and mortality occurring at shorter diabetes dur-
ation than T1D.5 The atherogenic metabolic milieu was
already present early in its natural history (within 5 years
of diagnosis) implying increased susceptibility to prema-
ture cardiovascular complications. This hypothesis was
supported by the ﬁndings of this study which showed
that patients with young-onset T2D experienced similar
burden (∼14%) of CVD at a much younger age (by ∼10
years) and at shorter diabetes duration (by ∼17 years),
compared to T1D. Glycemia was not a signiﬁcant pre-
dictive factor for CVD and this is consistent with Luk
et al8 who showed cardiometabolic risk factors (obesity,
hypertension, and dyslipidemia), rather than
Table 3 Prevalence of diabetes-related complications as stratified by diabetes duration
Diabetes duration (years)
0–10 10–20 >20
Type 1 Type 2 p Value Type 1 Type 2 p Value Type 1 Type 2 p Value
IHD (%) 0 5.7 <0.0005 2.6 9.9 0.005 9.1 28.5 <0.0005
Stroke (%) 0.5 1.4 NS 1.1 4.0 NS 2.7 7.9 0.01
PVD (%) 0.5 1.4 NS 1.6 1.3 NS 4.3 13.3 <0.0005
CVD (%) 1.0 8.1 0.001 4.7 14.6 0.002 13.7 38.2 <0.0005
Retinopathy (%) 1.5 3.8 NS 28.9 29.1 NS 53.9 60.0 NS
Neuropathy (%) 6.1 12.3 0.04 15.3 29.1 0.002 35.9 52.1 0.001
CVD, cardiovascular disease; IHD, ischemic heart disease; NS, not significant; PVD, peripheral vascular disease.
Table 4 Logistic regression analysis for predictors of diabetes complications
Cardiovascular disease Retinopathy Neuropathy
OR (95% CI) p Value OR (95% CI) p Value OR (95% CI) p Value
Age 1.08 (1.07 to 1.10) <0.0005 1.08 (1.07 to 1.09) <0.0005 1.08 (1.06 to 1.09) <0.0005
Sex 1.04 (0.75 to 1.45) NS 1.10 (0.87 to 1.39) NS 1.35 (1.05 to 1.75) 0.021
Diabetes duration 1.06 (1.05 to 1.07) <0.0005 1.10 (1.08 to 1.11) <0.0005 1.06 (1.05 to 1.08) <0.0005
HbA1c 1.04 (0.95 to 1.14) NS 1.11 (1.03 to 1.18) 0.003 1.15 (1.07 to 1.23) <0.0005
Creatinine 1.006 (1.003 to 1.010) <0.0005 1.016 (1.012 to 1.021) <0.0005 1.016 (1.012 to 1.021) <0.0005
Hypertension 7.75 (4.50 to 13.34) <0.0005 3.22 (2.46 to 4.22) <0.0005 3.36 (2.50 to 4.52) <0.0005
Dyslipidemia 2.15 (1.53 to 3.03) <0.0005 0.91 (0.72 to 1.15) NS 1.24 (0.96 to 1.59) NS
BMI>25 kg/m2 3.28 (1.90 to 5.68) <0.0005 1.39 (1.04 to 1.86) 0.026 1.50 (1.09 to 2.06) 0.012
Type of diabetes
(type 2 vs type 1)
2.04 (1.26 to 3.28)* 0.004 1.03 (0.74 to 1.44)† NS 1.47 (1.04 to 2.08)‡ 0.028
*Adjusted for age, diabetes duration, creatinine, hypertension, dyslipidemia, and BMI>25 kg/m2.
†Adjusted for age, diabetes duration, creatinine, hypertension, BMI>25 kg/m2, and HbA1c.
‡Adjusted for age, sex, diabetes duration, creatinine, hypertension, BMI>25 kg/m2, and HbA1c.
BMI, body mass index; HbA1c, glycated hemoglobin; NS, not significant.
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hyperglycemia, being the principal driver for CVD in
young adults with T2D.
In contrast, microvascular complications were strongly
associated with hyperglycemia in this study cohort.
Diabetes control was suboptimal in both types of young-
onset diabetes and hyperglycemia would have played an
important role in driving the burden of retinopathy and
neuropathy, accentuated by the increasing diabetes dur-
ation. Intensive treatment of glycemia has long-term
beneﬁcial effects of reducing microvascular as well as
macrovascular complications in T1D16 17 and older-onset
T2D.18 These data are crucially lacking in young-onset
T2D, particularly in regard to the legacy effect from
intensive glucose control within the ﬁrst few years of diag-
nosis. This issue is pertinent given its predisposition to
prolonged exposure to the adverse diabetic milieu.4
Obesity with associated dyslipidemia and hypertension is
a common feature in young-onset T2D which occurred to a
greater degree than T1D. The mean BMI for T2D of 33–
35 kg/m2 is consistent with that of other studies,5 19 and
this is signiﬁcantly higher than those of T1D (∼27 kg/m2).
Since obesity drives the atherogenic metabolic syndrome
components,20 the higher cardiovascular risk in young-
onset T2D is most likely attributable to the greater degree
of obesity. Obesity is instrumental to the rising incidence of
T2D in young people.21 Among young adults (mean age
∼34 years) who were at risk of T2D, almost 20% had abnor-
mal glucose metabolism and ∼90% were obese with a
mean BMI of 34 kg/m2.22 In the UK, NICE recommended
screening for diabetes in high-risk individuals aged 25–
39 years particularly from ethnic minority groups and those
with conditions that increase the risk of T2D,23 highlighting
the importance of early detection in young people.
The care of young people with diabetes has predomin-
antly focused on T1D, reﬂected by structured educational
programs and national guidelines on care pathways specif-
ically designed for this population.24 While young people
with T1D have an increased risk of adverse outcome,3 this
now holds true for T2D. The ﬁndings from this study and
others support this. Given its increasing incidence, the
emphasis of care of young people should also include T2D
which is often inappropriately perceived as ‘mild ’diabetes
due to its insidious onset. The asymptomatic period of dys-
glycemia prior to its diagnosis constitutes an unfavorable
metabolic milieu that predisposes to vascular damage,
which is further compounded by the prolonged exposure
to the diabetic phase. By using mathematical modeling,
Rhodes et al25 estimated that young-onset patients with
T2D will experience severe chronic complications by their
40s and the observation from this study of the signiﬁcant
burden of microvascular and macrovascular disease in this
age group concurs with their projection. Not surprisingly,
the life expectancy of young people diagnosed with
T2D between age 15 and 40 years is shortened by
8–15 years.25 26
The strengths of this study pertain to the relatively
large number of the young-onset T1D and T2D cohorts,
comparable with other studies.5 6 Moreover, steps were
taken to minimize the confounding bias of the different
age of onset and diabetes duration on complication
burden, a common dilemma in assessing complication
outcomes between T1D and T2D. However, there are
some study limitations. First, the absence of mortality
data precludes ascertainment of the cause of death, par-
ticularly from cardiovascular events. Second, it is difﬁcult
to determine the relative contributions of the various pre-
dictive factors on diabetes complications, given the cross-
sectional nature of this study. It is plausible that young-
onset T2D may not be an independent predictor of com-
plications if longitudinal data on factors such as glycemia,
hypertension, and dyslipidemia were available. Third, the
possibility of high-risk patients with young-onset T2D
being preferentially managed in hospital clinics cannot
be excluded, implying that the ﬁndings of this study may
not be extrapolated to the majority of patients with T2D
whose care is delivered in the community. However, the
complication risk proﬁle of the young-onset T2D cohort
in this study is similar to that of a large community-based
study with more than 300 general practices in the UK,27
indicating that this study cohort is likely to be representa-
tive of the young-onset T2D population overall. Fourth,
there were incomplete data on microalbuminuria and
proteinuria for T2D. However, the ﬁndings from this
study are consistent with those which included diabetic
renal complication,5 6 8 indicating that the observations
from this study most likely reﬂect the complication
proﬁle of young-onset T2D.
Several important clinical questions remain
unanswered which can guide directions for future
research. First, preventing T2D in the young is of utmost
importance given the intimate relationship between
obesity and its etiology. While there is good evidence for
reducing the incidence of T2D among high-risk adults,28
there are no similar data in children, adolescents, and
young adults. This issue is pertinent given that overweight
or obese children who remained obese as adults are at
risk of T2D and atherosclerotic complications.29 Second,
there is a suggestion that lifestyle intervention has a
minimal impact on weight loss, glycemic control, and dys-
lipidemia in young patients with T2D.30 31 Improving its
effectiveness with an appropriate model for structured
education to enhance patient empowerment and sustain
behavioral change is crucial. Third, randomized clinical
trials to assess the effectiveness of glycemia and risk factor
intervention on clinical outcomes in young-onset T2D
are lacking, in contrast to the older cohort32 and
T1D.3 16 17 Given the suboptimal diabetes control
observed in this study cohort and the importance of gly-
cemia as well as other cardiometabolic risk factors in the
etiology of microvascular and macrovascular complica-
tions, this is an important issue to address. Fourth, the
observation from the TODAY study33 of greater decline
in β cell function among adolescents with T2D compared
with older-onset patients merits further investigation into
its etiology. Fifth, the therapeutic effectiveness and safety
of newer agents such as GLP-1 agonist and SGLT-2
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inhibitor in reducing obesity and improving glycemic
control and durability need to be explored in young-
onset T2D, more so with the reduced therapeutic efﬁcacy
of metformin in this population.30 With the weight loss
beneﬁt, these medications can be an important compo-
nent of the treatment armamentarium.
In conclusion, evidence is accumulating to support
young-onset T2D being the more aggressive phenotype
than T1D to develop complications. More emphasis
should be placed on the care of young people with T2D
focusing not only on glycemia and risk factor interven-
tion but also improving adherence to treatment and a
healthy lifestyle. Since the majority of patients with T2D
are solely managed in the community, the challenge is
to raise this awareness among the primary care physi-
cians. Preventing T2D in high-risk young individuals is
also a vital strategy in addressing this burgeoning
problem. Robust evidence is lacking and more research
is needed to formulate and guide evidence-based care of
this increasingly prevalent population.
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